Chk1 Inhibition Ameliorates Alzheimer’s Disease Pathogenesis and Cognitive Dysfunction Through CIP2A/PP2A Signaling. This evidence concerns the gene CIP2A and early-onset autosomal dominant Alzheimer disease.